Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)
Permanent URI for this collectionhttps://hdl.handle.net/10668/22662
Browse
Recent Submissions
Item Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial.(2019) Bastidas, Adriana; de la Serna, Javier; El Idrissi, Mohamed; Oostvogels, Lidia; Quittet, Philippe; López-Jiménez, Javier; Vural, Filiz; Pohlreich, David; Zuckerman, Tsila; Issa, Nicolas C; Gaidano, Gianluca; Lee, Je-Jung; Abhyankar, Sunil; Solano, Carlos; Perez de Oteyza, Jaime; Satlin, Michael J; Schwartz, Stefan; Campins, Magda; Rocci, Alberto; Vallejo Llamas, Carlos; Lee, Dong-Gun; Tan, Sen Mui; Johnston, Anna M; Grigg, Andrew; Boeckh, Michael J; Campora, Laura; Lopez-Fauqued, Marta; Heineman, Thomas C; Stadtmauer, Edward A; Sullivan, Keith M; ZOE-HSCT Study Group CollaboratorsHerpes zoster, a frequent complication following autologous hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. A nonlive adjuvanted recombinant zoster vaccine has been developed to prevent posttransplantation zoster. To assess the efficacy and adverse event profile of the recombinant zoster vaccine in immunocompromised autologous HSCT recipients. Phase 3, randomized, observer-blinded study conducted in 167 centers in 28 countries between July 13, 2012, and February 1, 2017, among 1846 patients aged 18 years or older who had undergone recent autologous HSCT. Participants were randomized to receive 2 doses of either recombinant zoster vaccine (n = 922) or placebo (n = 924) administered into the deltoid muscle; the first dose was given 50 to 70 days after transplantation and the second dose 1 to 2 months thereafter. The primary end point was occurrence of confirmed herpes zoster cases. Among 1846 autologous HSCT recipients (mean age, 55 years; 688 [37%] women) who received 1 vaccine or placebo dose, 1735 (94%) received a second dose and 1366 (74%) completed the study. During the 21-month median follow-up, at least 1 herpes zoster episode was confirmed in 49 vaccine and 135 placebo recipients (incidence, 30 and 94 per 1000 person-years, respectively), an incidence rate ratio (IRR) of 0.32 (95% CI, 0.22-0.44; P Among adults who had undergone autologous HSCT, a 2-dose course of recombinant zoster vaccine compared with placebo significantly reduced the incidence of herpes zoster over a median follow-up of 21 months. ClinicalTrials.gov Identifier: NCT01610414.Item Sandwich-Type Electrochemical Paper-Based Immunosensor for Claudin 7 and CD81 Dual Determination on Extracellular Vesicles from Breast Cancer Patients.(American Chemical Society, 2021-01-19) Ortega, Francisco G; Regiart, Matias D; Rodriguez-Martinez, Alba; de-Miguel-Perez, Diego; Serrano, Maria J; Lorente, Jose A; Tortella, Gonzalo; Rubilar, Olga; Sapag, Karim; Bertotti, Mauro; Fernandez-Baldo, Martin AThis study is focused on identifying novel epithelial markers in circulating extracellular vesicles (EVs) through the development of a dual sandwich-type electrochemical paper-based immunosensor for Claudin 7 and CD81 determination, as well as its validation in breast cancer (BC) patients. This immunosensor allows for rapid, sensitive, and label-free detection of these two relevant BC biomarkers. Under optimum conditions, the limit of detection for Claudin 7 was 0.4 pg mL-1, with a wide linear range of 2 to 1000 pg mL-1, while for CD81, the limit of detection was 3 pg mL-1, with a wide linear range of 0.01 to 10 ng mL-1. Finally, we validated Claudin 7 and CD81 determination in EVs from 60 BC patients and 20 healthy volunteers, reporting higher diagnostic accuracy than the one observed with classical diagnostic markers. This analysis provides a low-cost, specific, versatile, and user-friendly strategy as a robust and reliable tool for early BC diagnosis.Item Correlation between genomic alterations and germline mutations in men with metastatic castration-resistant prostate cancer (mCRPC)(Elsevier, 2021-09-21) Llacer Perez, C.; Oliva Fernandez, L.; Canada-Higueras, E.; Saez, M. I.; Villatoro, R.; Montesa Pino, A.; Herrera Imbroda, B.; Hernandez, D.; Lozano Mejorada, R.; Romero Laorden, N.; Marquez, M.; Grau, G.; Pineda, A.; Lopez, F. J.; Peinado, P.; Alameda, D.; Olmos, D.; Castro, E.; [Llacer Perez, C.] Hosp Univ Virgen Victoria, Dept Med Oncol, Malaga, Spain; [Oliva Fernandez, L.] Hosp Univ Virgen Victoria, Dept Med Oncol, Malaga, Spain; [Saez, M. I.] Hosp Univ Virgen Victoria, Dept Med Oncol, Malaga, Spain; [Marquez, M.] Hosp Univ Virgen Victoria, Dept Med Oncol, Malaga, Spain; [Grau, G.] Hosp Univ Virgen Victoria, Dept Med Oncol, Malaga, Spain; [Lopez, F. J.] Hosp Univ Virgen Victoria, Dept Med Oncol, Malaga, Spain; [Castro, E.] Hosp Univ Virgen Victoria, Dept Med Oncol, Malaga, Spain; [Canada-Higueras, E.] Genol Med, Genet Testing, Malaga, Spain; [Villatoro, R.] Hosp Costa Sol, Dept Med Oncol, Marbella, Spain; [Montesa Pino, A.] Hosp Reg Univ Malaga Carlos Haya, Oncol, Malaga, Spain; [Herrera Imbroda, B.] Hosp Univ Virgen Victoria, Biomed Res Inst Malaga IBIMA, Genitourinary Oncol Traslat Res Grp, Urol Unit, Malaga, Spain; [Hernandez, D.] Hosp Reg Univ Malaga, Urol Unit, Malaga, Spain; [Lozano Mejorada, R.] CNIO Ctr Nacl Invest Oncol, Dept Prostate Canc Clin Res, Madrid, Spain; [Romero Laorden, N.] CNIO Ctr Nacl Invest Oncol, Dept Prostate Canc Clin Res, Madrid, Spain; [Pineda, A.] Biomed Res Inst Malaga IBIMA, Genitourinary Oncol Traslat Res Grp, Malaga, Spain; [Peinado, P.] Biomed Res Inst Malaga IBIMA, Genitourinary Oncol Traslat Res Grp, Malaga, Spain; [Alameda, D.] Biomed Res Inst Malaga IBIMA, Genitourinary Oncol Traslat Res Grp, Malaga, Spain; [Olmos, D.] CNIO Ctr Nacl Invest Oncol, Prostate Canc, Madrid, Spain; Instituto de Salud Carlos IIIItem Treatment in CARD eligible metastatic castration resistant prostate cancer (mCRPC) patients according to the status of germline HRR mutations: Cabazitaxel (CBZ) vs enzalutamide/abiraterone(Elsevier, 2020-09-01) Llacer Perez, C.; Romero Laorden, N.; Lozano Mejorada, R.; Piulats, J. M.; Puente, J.; Lorente Estelles, D.; Medina, A.; Cattrini, C.; Vitrone, F. M.; Almagro, E.; Borrega Garcia, P.; Lainez, N.; Rivera, L.; Villatoro, R.; Hernandez, A.; Rodriguez-Vida, A.; Lopez-Casas, P. P.; Gallardo, E.; Castro Marcos, E.; Olmos Hidalgo, D.; [Llacer Perez, C.] Hosp Univ Virgen de la Victoria & Reg, Inst Invest Biomed Malaga IBIMA, Med Oncol Dept, CNIO IBIMA Unit, Malaga, Spain; [Romero Laorden, N.] CNIO Ctr Nacl Invest Oncol, Prostate Canc, Madrid, Spain; [Lozano Mejorada, R.] CNIO Ctr Nacl Invest Oncol, Prostate Canc Clin Res Unit, Madrid, Spain; [Cattrini, C.] CNIO Ctr Nacl Invest Oncol, Prostate Canc Clin Res Unit, Madrid, Spain; [Rivera, L.] CNIO Ctr Nacl Invest Oncol, Prostate Canc Clin Res Unit, Madrid, Spain; [Lopez-Casas, P. P.] CNIO Ctr Nacl Invest Oncol, Prostate Canc Clin Res Unit, Madrid, Spain; [Piulats, J. M.] Catalan Inst Oncol, Med Oncol, Barcelona, Spain; [Puente, J.] Hosp Clin Univ San Carlos, Dept Med Oncol, Madrid, Spain; [Lorente Estelles, D.] Hosp Gen Univ Castellon, Med Oncol Dept, Castellon de La Plana, Spain; [Medina, A.] Ctr Oncol Galicia, Med Oncol Dept, La Coruna, Spain; [Vitrone, F. M.] CNIO Ctr Nacl Invest Oncol, Dept Med Oncol, Madrid, Spain; [Almagro, E.] Hosp Univ Quironsalud Madrid, Med Oncol Dept, Pozuelo De Alarcon, Spain; [Borrega Garcia, P.] Hosp San Pedro de Alcantara, Med Oncol Dept, Caceres, Spain; [Lainez, N.] Complejo Hosp Navarra, Med Oncol Dept, Pamplona, Spain; [Villatoro, R.] Hosp Univ Costa del Sol, Med Oncol Dept, Marbella, Spain; [Hernandez, A.] Inst Oncol, Onkologikoa, Donostia San Sebastian, Spain; [Rodriguez-Vida, A.] Hosp Mar, Med Oncol Dept, Barcelona, Spain; [Gallardo, E.] Univ Autonoma Barcelona, Med Oncol Dept, Parc Tauli Hosp Univ, Inst Invest & Innovacio Parc Tauli I3PT, Barcelona, Spain; [Castro Marcos, E.] Hosp Univ Virgen de la Victoria, Med Oncol, Malaga, Spain; [Castro Marcos, E.] Inst Invest Biomed Malaga, Malaga, Spain; [Olmos Hidalgo, D.] CNIO Spanish Natl Canc Ctr, Prostate Canc Clin Res Unit, Madrid, SpainItem Quality of life and survival in elderly metastatic castration-resistant prostate cancer (mCRPC) patients (Pts) treated with docetaxel(Elsevier, 2020-09-01) Paredero Perez, I.; Arnal, M.; Lorente, D.; Girones Sarrio, R.; Lozano Mejorada, R.; Romero Laorden, N.; Llacer Perez, C.; Castro Marcos, E.; Olmos, D.; Sanchez Hernandez, A.; [Paredero Perez, I.] Consorcio Hosp Prov Castellon, Med Oncol Dept, Castellon De La Plana, Spain; [Arnal, M.] Consorcio Hosp Prov Castellon, Med Oncol Dept, Castellon De La Plana, Spain; [Lorente, D.] Consorcio Hosp Prov Castellon, Med Oncol Dept, Castellon De La Plana, Spain; [Sanchez Hernandez, A.] Consorcio Hosp Prov Castellon, Med Oncol Dept, Castellon De La Plana, Spain; [Girones Sarrio, R.] Hosp Univ & Politecn La Fe, Hosp Univ & Politecn FE Valencia, IIS La Fe Inst Invest Sanitaria La Fe, Valencia, Spain; [Lozano Mejorada, R.] CNIO Ctr Nacl Invest Oncol, Dept Med Oncol, Madrid, Spain; [Romero Laorden, N.] Hosp Univ Princesa, Med Oncol Dept, Madrid, Spain; [Llacer Perez, C.] Hosp Univ Virgen de la Victoria, Med Oncol Dept, Malaga, Spain; [Castro Marcos, E.] Hosp Univ Virgen de la Victoria, Med Oncol, Malaga, Spain; [Castro Marcos, E.] Inst Invest Biomed Malaga, Malaga, Spain; [Olmos, D.] Spanish Natl Canc Res Ctr CNIO, Madrid, Spain; [Olmos, D.] Hosp Univ Virgen de la Victoria & Reg Malaga, Malaga, SpainItem Importance of research nursing role determining the germline study in metastatic prostate cancer patients(Elsevier, 2021-09-21) Ferreira, P. Peinado; Perez, C. Llacer; Grau, G.; Fernandez, L. Oliva; Canada-Higueras, E.; Herrera-Imbroda, B.; Hernandez, D.; Saez, M. I.; Villatoro, R.; Pino, A. Montesa; Lopez, F. J.; Marquez, M.; Pineda, A.; Olmos, D.; Castro, E.; [Ferreira, P. Peinado] Biomed Res Inst Malaga IBIMA, Genitourinary Tumor Unit, Malaga, Spain; [Grau, G.] Biomed Res Inst Malaga IBIMA, Genitourinary Tumor Unit, Malaga, Spain; [Lopez, F. J.] Biomed Res Inst Malaga IBIMA, Genitourinary Tumor Unit, Malaga, Spain; [Marquez, M.] Biomed Res Inst Malaga IBIMA, Genitourinary Tumor Unit, Malaga, Spain; [Pineda, A.] Biomed Res Inst Malaga IBIMA, Genitourinary Tumor Unit, Malaga, Spain; [Perez, C. Llacer] Hosp Clin Virgen Victoria, Med Oncol Dept, Malaga, Spain; [Fernandez, L. Oliva] Hosp Clin Virgen Victoria, Med Oncol Dept, Malaga, Spain; [Saez, M. I.] Hosp Clin Virgen Victoria, Med Oncol Dept, Malaga, Spain; [Canada-Higueras, E.] Genol Med, Genet Testing, Malaga, Spain; [Herrera-Imbroda, B.] Hosp Univ Virgen Victoria, Biomed Res Inst Malaga IBIMA, Urol Unit, Malaga, Spain; [Hernandez, D.] Hosp Reg Univ, Urol, Malaga, Spain; [Villatoro, R.] Hosp Costa Sol, Agencia Sanitaria Costa Sol, Med Oncol, Marbella, Spain; [Pino, A. Montesa] Hosp Reg Univ Malaga Carlos Haya, Oncol, Malaga, Spain; [Olmos, D.] CNIO Ctr Nacl Invest Oncol, Med Oncol Dept, Madrid, Spain; [Castro, E.] Hosp Clin Virgen Victoria, Med Oncol Dept, Malaga, SpainItem Accuracy and Safety of Nasal Allergen Challenge in Asthmatic and Non-Asthmatic Patients(Mosby-elsevier, 2019-02-01) Rondon, Carmen; Eguiluz-Gracia, Ibon; Verge, Jesus; Gomez, Francisca; Espino, Teresa; Barrionuevo, Esther; Bogas, Gador; Cardenas, Natalia; Jurado-Escobar, Raquel; Campo, Paloma; Torres Jaen, Maria Jose; [Rondon, Carmen] Hosp Reg Univ Malaga IBIMA, Malaga, Spain; [Eguiluz-Gracia, Ibon] Hosp Reg Univ Malaga IBIMA, Malaga, Spain; [Gomez, Francisca] Hosp Reg Univ Malaga IBIMA, Malaga, Spain; [Espino, Teresa] Hosp Reg Univ Malaga IBIMA, Malaga, Spain; [Barrionuevo, Esther] Hosp Reg Univ Malaga IBIMA, Malaga, Spain; [Cardenas, Natalia] Hosp Reg Univ Malaga IBIMA, Malaga, Spain; [Campo, Paloma] Hosp Reg Univ Malaga IBIMA, Malaga, Spain; [Verge, Jesus] Hosp Virgen de la Victoria IBIMA, Malaga, Spain; [Bogas, Gador] UMA, Allergy Unit, IBIMA, Reg Univ Hosp Malaga, Malaga, Spain; [Torres Jaen, Maria Jose] UMA, Allergy Unit, IBIMA, Reg Univ Hosp Malaga, Malaga, Spain; [Jurado-Escobar, Raquel] UMA, Res Lab, IBIMA, Reg Univ Hosp Malaga, Malaga, SpainItem Survival and prognostic factors analysis of 535 grade 3 gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN): Data from the Spanish Taskforce of Neuroendocrine Tumours Registry (R-GETNE)(Elsevier, 2020-09-01) Jimenez Fonseca, P.; La Salvia, A.; Capdevila, J.; Castano, A.; Benavent, M.; Alonso-Orduna, V.; Alonso, T.; Sanchez Canovas, M.; Custodio, A.; Garcia Centeno, R.; Llanos, M.; Crespo, G.; Lopez de Sa, A.; Teule, A.; Oliva Fernandez, L.; Torres, I.; Gallego Plazas, J.; Pericay, C.; Villabona, C.; Lopez, C.; [Jimenez Fonseca, P.] Hosp Univ Cent Asturias, Med Oncol, Oviedo, Spain; [La Salvia, A.] Hosp Univ 12 Octubre, Med Oncol, Madrid, Spain; [Capdevila, J.] Vall Hebron Univ Hosp Inst Oncol, Gastrointestinal & Endocrine Tumor, Barcelona, Spain; [Castano, A.] Hosp Univ Fuenlabrada, Pathol, Madrid, Spain; [Benavent, M.] Hosp Univ Virgen del Rocio, Med Oncol, Seville, Spain; [Alonso-Orduna, V.] Hosp Univ Miguel Servet, Med Oncol, Zaragoza, Spain; [Alonso, T.] Hosp Univ Ramon & Cajal, Med Oncol, Madrid, Spain; [Sanchez Canovas, M.] Hosp Univ Morales Meseguer, Med Oncol, Murcia, Spain; [Custodio, A.] Hosp Univ La Paz, Med Oncol, Madrid, Spain; [Garcia Centeno, R.] Hosp Univ Gregorio Maranon, Endocrinol & Nutr, Madrid, Spain; [Llanos, M.] Hosp Univ Canarias, Med Oncol, Santa Cruz De Tenerife, CA, Spain; [Crespo, G.] Hosp Univ Burgos, Med Oncol, Burgos, Spain; [Lopez de Sa, A.] Hosp Univ Clinico San Carlos, Med Oncol, Madrid, Spain; [Teule, A.] Catalan Inst Oncol, Hereditary Canc Program, Med Oncol, Barcelona, Spain; [Oliva Fernandez, L.] Hosp Univ Reg & Virgen de la Victoria Malaga, Inst Invest Biomed Malaga IBIMA, Invest Clin & Traslac Canc, Med Oncol, Malaga, Spain; [Torres, I.] Hosp Univ Lozano Bleza, Med Oncol, Zaragoza, Spain; [Gallego Plazas, J.] Hosp Gen Univ Elche, Med Oncol, Elche, Spain; [Pericay, C.] Hosp Sabadell Corporacis Parc Tauli, Med Oncol, Sabadell, Spain; [Villabona, C.] Hosp Univ Bellvitge, Endocrinol & Nutr, Barcelona, Spain; [Lopez, C.] Hosp Univ Marques Valdecilla, Med Oncol, Santander, Spain; IpsenItem Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multicohort phase II trial (CABATEN trial / GETNE-T1914)(Elsevier, 2021-09-21) Grande, E.; Garcia-Carbonero, R.; Teule, A.; Benavent Vinuales, M.; Jimenez-Fonseca, P.; Molina-Cerrillo, J.; Lopez, C.; Custodio, A.; Hierro, C.; Gallego, J.; Alonso, V.; Carmona-Bayonas, A.; Llanos, M.; Sevilla, I.; Hernando, J.; Lista, F.; Anton Pascual, B.; Ruffinelli, J. C.; Gallego Jimenez, I.; Capdevila, J.; [Grande, E.] MD Anderson Canc Ctr Madrid, Dept Med Oncol, Madrid, Spain; [Garcia-Carbonero, R.] UCM, Hosp Univ Octubre 12, Dept Med Oncol, Imas 12, Madrid, Spain; [Anton Pascual, B.] UCM, Hosp Univ Octubre 12, Dept Med Oncol, Imas 12, Madrid, Spain; [Teule, A.] Inst Catala Oncol ICO IDIBELL, Dept Med Oncol, Lhospitalet De Llobregat, Spain; [Ruffinelli, J. C.] Inst Catala Oncol ICO IDIBELL, Dept Med Oncol, Lhospitalet De Llobregat, Spain; [Benavent Vinuales, M.] Univ Hosp Virgen del Rocio, Inst Biomed Sevilla IBIS, Dept Med Oncol, Seville, Spain; [Gallego Jimenez, I.] Univ Hosp Virgen del Rocio, Inst Biomed Sevilla IBIS, Dept Med Oncol, Seville, Spain; [Jimenez-Fonseca, P.] Hosp Univ Cent Asturias, Dept Med Oncol, ISPA, Oviedo, Spain; [Molina-Cerrillo, J.] Hosp Univ Ramon & Cajal, Dept Med Oncol, Madrid, Spain; [Lopez, C.] Hosp Univ Marques de Valdecilla, Dept Med Oncol, IDIVAL, Santander, Spain; [Custodio, A.] Hosp Univ La Paz, Dept Med Oncol, Madrid, Spain; [Hierro, C.] Germans Trias & Pujol Univ Hosp, Dept Med Oncol, Catalan Inst Oncol ICO Badalona, Badalona, Spain; [Gallego, J.] Gen Univ Elche Hosp, Dept Med Oncol, Alicante, Spain; [Alonso, V.] Hosp Univ Miguel Servet, Inst Aragones Invest Sanitaria, Dept Med Oncol, Zaragoza, Spain; [Carmona-Bayonas, A.] IMIB, Hosp Univ Morales Meseguer, Hematol & Med Oncol Dept, UMI, Murcia, Spain; [Llanos, M.] Hosp Univ Canarias, Dept Med Oncol, San Cristobal La Laguna, Spain; [Sevilla, I.] Hosp Univ Reg & Virgen Victoria Malaga, Dept Med Oncol, Inst Invest Biomed Malaga IBIMA, Invest Clin & Traslac Canc, Malaga, Spain; [Hernando, J.] Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain; [Capdevila, J.] Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain; [Lista, F.] MD Anderson Canc Ctr Madrid, Dept Urol, Madrid, Spain; Ipsen; RocheAntiangiogenic agents have demonstrated antitumor properties in endocrine malignancies regardless of their primary origin. Experience with immune-checkpoint inhibitors is limited in this area and early results when used as single agents are discouraging. The aim of this trial is to assess the efficacy and safety of the combination of cabozantinib and atezolizumab, which may overcome the resistance in previously treated metastatic endocrine tumors .Item Durvalumab plus tremelimumab in patients with grade 3 neuroendocrine neoplasms of gastroenteropancreatic origin: Updated results from the multicenter phase II DUNE trial (GETNE 1601)(Elsevier, 2021-09-21) Capdevila, J.; Landolfi, S.; Hernando, J.; Teule, A.; Garcia-Carbonero, R.; Custodio, A.; Cubillo, A.; Alonso-Gordoa, T.; Carmona-Bayonas, A.; Crespo, G.; Blanco, M.; Viudez, A.; La Casta, A.; Sevilla, I.; Segura, A.; Lopez, C.; Benavent Vinuales, M.; Nuciforo, P.; Manzano, J. L.; [Capdevila, J.] Vall Hebron Inst Oncol VHIO, Vall Hebron Univ Hosp, Dept Med Oncol, Barcelona, Spain; [Hernando, J.] Vall Hebron Inst Oncol VHIO, Vall Hebron Univ Hosp, Dept Med Oncol, Barcelona, Spain; [Landolfi, S.] Vall Hebron Univ Hosp, Dept Pathol, Barcelona, Spain; [Teule, A.] Inst Catala Oncol ICO IDIBELL, Dept Med Oncol, Lhospitalet De Llobregat, Spain; [Garcia-Carbonero, R.] Hosp Univ 12 Octubre, Dept Med Oncol, UCM, CNIO,IMAS12, Madrid, Spain; [Custodio, A.] Hosp Univ La Paz, Dept Med Oncol, Madrid, Spain; [Cubillo, A.] Hosp Univ HM Sanchinarro, Med Oncol Dept, Madrid, Spain; [Alonso-Gordoa, T.] Hosp Univ Ramon & Cajal, Med Oncol, Madrid, Spain; [Carmona-Bayonas, A.] Hosp Univ Morales Meseguer, Hematol & Med Oncol Dept, UMU, IMIB, Murcia, Spain; [Crespo, G.] Complejo Asistencial Univ Burgos, Dept Med Oncol, Burgos, Spain; [Blanco, M.] Hosp Univ Gregorio Maranon, Dept Med Oncol, Madrid, Spain; [Viudez, A.] Complejo Hosp Navarra, Medica Oncol Dept, Pamplona, Spain; [La Casta, A.] Hosp Univ Donostia, Dept Med Oncol, San Sebastian, Spain; [Sevilla, I.] Hosp Univ Reg & Virgen Victoria Malaga, Med Oncol Dept, Inst Invest Biomed Malaga IBIMA, Invest Clin Traslac & Canc, Malaga, Spain; [Segura, A.] Hosp Univ Fe, Dept Med Oncol, Valencia, Spain; [Lopez, C.] Hosp Univ Marques Valdecilla, Dept Med Oncol, IDIVAL, Santander, Spain; [Benavent Vinuales, M.] Univ Hosp Virgen Rocio, Inst Biomed Sevilla IBIS, Dept Med Oncol, Seville, Spain; [Nuciforo, P.] Vall Hebron Inst Oncol VHIO, Mol Oncol Grp, Barcelona, Spain; [Manzano, J. L.] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol ICO Badalona, Dept Med Oncol, Badalona, Spain; AstraZenecaBackground.Previously reported treatment efficacy with durvalumab (D) plus tremelimumab (T) showed limited activity in patients (pts) with well differentiated neuroendocrine tumors (NETs). However, primary endpoint was achieved in grade 3 (G3) neuroendocrine neoplasms (NENs) suggesting a promising overall survival rate in a pretreated population. Here we update the results of the G3 cohort with central pathological review.Methods.DUNE was a prospective open-label trial that recruited pts with advanced NENs after progression to standard therapies in four cohorts (C1-4): typical/atypical lung carcinoids (C1), G1/2 gastrointestinal (C2), G1/2 pancreatic (C3), and G3 NENs of gastroenteropancreatic origin after progression to first-line platinum-based chemotherapy (C4). Pts received 1500 mg durvalumab (D) (up to 13 cycles) plus 75 mg tremelimumab (T)(up to 4 cycles) once every 4 weeks. Primary objective for C4 was the 9 months (m) overall survival rate (OS) expected to be over 23%.Item Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort(Bmj publishing group, 2023-02) Kullmann, Friederike; Strissel, Pamela L.; Strick, Reiner; Stoehr, Robert; Eckstein, Markus; Bertz, Simone; Wullich, Bernd; Sikic, Danijel; Wach, Sven; Taubert, Helge; Olbert, Peter; Heers, Hendrik; Lara, Maria Fernanda; Macias, Maria Luisa; Matas-Rico, Elisa; Lozano, Maria Jose ; Prieto, Daniel; Hierro, Isabel; van-Doeveren, Thomas; Bieche, Ivan; Masliah-Planchon, Julien; Beaurepere, Romane; Boormans, Joost L.; Allory, Yves; Herrera-Imbroda, Bernardo; Hartmann, Arndt; Weyerer, Veronika; [Kullmann, Friederike] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen NUrnberg, Inst Pathol, Erlangen, Germany; [Strissel, Pamela L.] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen NUrnberg, Inst Pathol, Erlangen, Germany; [Stoehr, Robert] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen NUrnberg, Inst Pathol, Erlangen, Germany; [Eckstein, Markus] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen NUrnberg, Inst Pathol, Erlangen, Germany; [Bertz, Simone] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen NUrnberg, Inst Pathol, Erlangen, Germany; [Hartmann, Arndt] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen NUrnberg, Inst Pathol, Erlangen, Germany; [Weyerer, Veronika] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen NUrnberg, Inst Pathol, Erlangen, Germany; [Strissel, Pamela L.] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen Nurnberg, Dept Gynecol & Obstet, Lab Mol Med, Erlangen, Germany; [Strick, Reiner] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen Nurnberg, Dept Gynecol & Obstet, Lab Mol Med, Erlangen, Germany; [Strick, Reiner] Comprehens Canc Ctr Erlangen EMN CCC ER EMN, Erlangen, Germany; [Stoehr, Robert] Comprehens Canc Ctr Erlangen EMN CCC ER EMN, Erlangen, Germany; [Eckstein, Markus] Comprehens Canc Ctr Erlangen EMN CCC ER EMN, Erlangen, Germany; [Bertz, Simone] Comprehens Canc Ctr Erlangen EMN CCC ER EMN, Erlangen, Germany; [Wullich, Bernd] Comprehens Canc Ctr Erlangen EMN CCC ER EMN, Erlangen, Germany; [Sikic, Danijel] Comprehens Canc Ctr Erlangen EMN CCC ER EMN, Erlangen, Germany; [Wach, Sven] Comprehens Canc Ctr Erlangen EMN CCC ER EMN, Erlangen, Germany; [Taubert, Helge] Comprehens Canc Ctr Erlangen EMN CCC ER EMN, Erlangen, Germany; [Hartmann, Arndt] Comprehens Canc Ctr Erlangen EMN CCC ER EMN, Erlangen, Germany; [Weyerer, Veronika] Comprehens Canc Ctr Erlangen EMN CCC ER EMN, Erlangen, Germany; [Wullich, Bernd] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Urol & Pediat Urol, Erlangen, Germany; [Sikic, Danijel] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Urol & Pediat Urol, Erlangen, Germany; [Wach, Sven] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Urol & Pediat Urol, Erlangen, Germany; [Taubert, Helge] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Urol & Pediat Urol, Erlangen, Germany; [Olbert, Peter] Privatklin Brixsana, Urol, Brixen, Italy; [Heers, Hendrik] Univ Hosp Giessen & Marburg, Dept Urol & Pediat Urol, Marburg, Germany; [Fernanda Lara, Maria] Virgen de la Victoria Univ Hosp Malaga, Inst Invest Biomed Malaga, Dept Urol, Malaga, Spain; [Herrera-Imbroda, Bernardo] Virgen de la Victoria Univ Hosp Malaga, Inst Invest Biomed Malaga, Dept Urol, Malaga, Spain; [Fernanda Lara, Maria] Inst Invest Biomed Malaga, Genitourinary Canc Translat Res Grp, Malaga, Spain; [Luisa Macias, Maria] Inst Invest Biomed Malaga, Genitourinary Canc Translat Res Grp, Malaga, Spain; [Matas-Rico, Elisa] Inst Invest Biomed Malaga, Genitourinary Canc Translat Res Grp, Malaga, Spain; [Herrera-Imbroda, Bernardo] Inst Invest Biomed Malaga, Genitourinary Canc Translat Res Grp, Malaga, Spain; [Matas-Rico, Elisa] Malaga Univ, Dept Cell Biol Genet & Physiol, Malaga, Spain; [Jose Lozano, Maria] Univ Malaga, Fac Med, Dept Pathol, Malaga, Spain; [Jose Lozano, Maria] Hosp Univ Virgen de la Victoria, Inst Invest Biomed Malaga IBIMA, Malaga, Spain; [Prieto, Daniel] Hosp Univ Virgen de la Victoria, Inst Invest Biomed Malaga IBIMA, Unidad Gest Clin Patol, Dept Pathol, Malaga, Spain; [Hierro, Isabel] Hosp Univ Virgen de la Victoria, Inst Invest Biomed Malaga IBIMA, Unidad Gest Clin Patol, Dept Pathol, Malaga, Spain; [van Doeveren, Thomas] Erasmus MC Canc Inst, Univ Med Ctr, Dept Urol, Rotterdam, Netherlands; [Boormans, Joost L.] Erasmus MC Canc Inst, Univ Med Ctr, Dept Urol, Rotterdam, Netherlands; [Bieche, Ivan] PSL Res Univ, Inst Curie, Dept Genet, Paris, France; [Masliah-Planchon, Julien] PSL Res Univ, Inst Curie, Dept Genet, Paris, France; [Beaurepere, Romane] PSL Res Univ, Inst Curie, Dept Genet, Paris, France; [Allory, Yves] Rene Huguenin Curie Inst, Dept Pathol, Paris, FranceAims Upper tract urothelial carcinoma (UTUC) is a rare malignancy with a poor prognosis which occurs sporadically or in few cases results from a genetic disorder called Lynch syndrome. Recently, examination of microsatellite instability (MSI) has gained importance as a biomarker: MSI tumours are associated with a better response to immunomodulative therapies. Limited data are known about the prevalence of MSI in UTUC. New detection methods using the fully automated Idylla MSI Assay facilitate analysis of increased patient numbers. Methods We investigated the frequency of MSI in a multi-institutional cohort of 243 consecutively collected UTUC samples using standard methodology (Bethesda panel), along with immunohistochemistry of mismatch repair (MMR) proteins. The same tumour cohort was retested using the Idylla MSI Assay by Biocartis. Results Using standard methodology, 230/243 tumours were detected as microsatellite stable (MSS), 4/243 tumours as MSI and 9/243 samples as invalid. In comparison, the Idylla MSI Assay identified four additional tumours as MSS, equalling 234/243 tumours; 4/243 were classified as MSI and only 5/243 cases as invalid. At the immunohistochemical level, MSI results were supported in all available cases with a loss in MMR proteins. The overall concordance between the standard and the Idylla MSI Assay was 98.35%. Time to result differed between 3 hours for Idylla MSI Assay and 2 days with the standard methodology. Conclusion Our data indicate a low incidence rate of MSI tumours in patients with UTUC. Furthermore, our findings highlight that Idylla MSI Assay can be applied as an alternative method of MSI analysis for UTUC.Item LUNG ULTRASOUND UTILITY IN INTERSTITIAL LUNG DISEASE DETECTION IN RHEUMATOID ARTHRITIS(Bmj publishing group, 2020-06-01) Godoy-Navarrete, F.; Jimenez-Nunez, F. G.; Mena-Vazquez, N.; Romero-Barco, C. M.; Diaz Cordoves, G.; Fernandez-Nebro, A.; [Godoy-Navarrete, F.] Univ Malaga, Hosp Reg Univ Malaga, Inst Invest Biomed Malaga IBIMA, UGC Reumatol, Malaga, Spain; [Jimenez-Nunez, F. G.] Univ Malaga, Hosp Reg Univ Malaga, Inst Invest Biomed Malaga IBIMA, UGC Reumatol, Malaga, Spain; [Mena-Vazquez, N.] Univ Malaga, Hosp Reg Univ Malaga, Inst Invest Biomed Malaga IBIMA, UGC Reumatol, Malaga, Spain; [Diaz Cordoves, G.] Univ Malaga, Hosp Reg Univ Malaga, Inst Invest Biomed Malaga IBIMA, UGC Reumatol, Malaga, Spain; [Fernandez-Nebro, A.] Univ Malaga, Hosp Reg Univ Malaga, Inst Invest Biomed Malaga IBIMA, UGC Reumatol, Malaga, Spain; [Romero-Barco, C. M.] Hosp Univ Virgen Victoria, UGC Reumatol, Malaga, SpainItem RHEUMATOID ARTHRITIS REFRACTORY TO BIOLOGICAL TREATMENT(Bmj publishing group, 2020-06-01) Caparros-Ruiz, R.; Romero-Barco, C. M.; Mena-Vazquez, N.; Redondo, R.; Ordonez Canizares, M. D. C.; Fernandez-Nebro, A.; [Caparros-Ruiz, R.] Univ Malaga, Inst Invest Biomed Malaga IBIMA, Hosp Reg Univ Malaga HRUM, UGC Reumatol, Malaga, Spain; [Mena-Vazquez, N.] Univ Malaga, Inst Invest Biomed Malaga IBIMA, Hosp Reg Univ Malaga HRUM, UGC Reumatol, Malaga, Spain; [Redondo, R.] Univ Malaga, Inst Invest Biomed Malaga IBIMA, Hosp Reg Univ Malaga HRUM, UGC Reumatol, Malaga, Spain; [Ordonez Canizares, M. D. C.] Univ Malaga, Inst Invest Biomed Malaga IBIMA, Hosp Reg Univ Malaga HRUM, UGC Reumatol, Malaga, Spain; [Fernandez-Nebro, A.] Univ Malaga, Inst Invest Biomed Malaga IBIMA, Hosp Reg Univ Malaga HRUM, UGC Reumatol, Malaga, Spain; [Caparros-Ruiz, R.] Hosp Univ Vall dHebron, Rheumatol Serv, Barcelona, Spain; [Romero-Barco, C. M.] Univ Malaga, Inst Invest Biomed Malaga IBIMA, Hosp Clin Virgen Victoria Malaga HCUVV, UGC Reumatol, Malaga, SpainItem ANALYSIS OF INTESTINAL MICROBIOME PROFILE OF PATIENTSWITH ESTABLISHED RHEUMATOID ARTHRITIS AND HEALTHY CONTROLS(Bmj publishing group, 2019-06-01) Mena-Vazquez, Natalia; Ruiz-Limon, Patricia; Moreno-Indias, Isabel; Manrique Arija, Sara; Jose Tinahones, Francisco; Fernandez-Nebro, Antonio; [Mena-Vazquez, Natalia] Univ Malaga, Inst Invest Biomed Malaga IBIMA, Hosp Reg Univ Malaga, UGC Reumatol, Malaga, Spain; [Manrique Arija, Sara] Univ Malaga, Inst Invest Biomed Malaga IBIMA, Hosp Reg Univ Malaga, UGC Reumatol, Malaga, Spain; [Fernandez-Nebro, Antonio] Univ Malaga, Inst Invest Biomed Malaga IBIMA, Hosp Reg Univ Malaga, UGC Reumatol, Malaga, Spain; [Ruiz-Limon, Patricia] Hosp Clin Virgen Victoria, Inst Invest Biomed Malaga IBIMA, Unidad Gest Clin Endocrinol & Nutr, Malaga, Spain; [Moreno-Indias, Isabel] Hosp Clin Virgen Victoria, Inst Invest Biomed Malaga IBIMA, Unidad Gest Clin Endocrinol & Nutr, Malaga, Spain; [Jose Tinahones, Francisco] Hosp Clin Virgen Victoria, Inst Invest Biomed Malaga IBIMA, Unidad Gest Clin Endocrinol & Nutr, Malaga, Spain; [Moreno-Indias, Isabel] Inst Salud Carlos III, CIBER Fisiopatol Obesidad & Nutr CIBEROBN, Malaga, Spain; [Jose Tinahones, Francisco] Inst Salud Carlos III, CIBER Fisiopatol Obesidad & Nutr CIBEROBN, Malaga, SpainItem ANALYSIS OF CLINICAL-ANALYTICAL CHARACTERISTICS IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) AND INTERSTITIAL LUNG DISEASE (ILD): CASE-CONTROL STUDY(Bmj publishing group, 2018-06-01) Mena-Vazquez, N.; Manrique-Arija, S.; Romero-Barco, C.; Urena-Garnica, I.; Ordonez-Canizares, M.; Jimenez-Nunez, F.; Diaz-Cordoves, G.; Rojas-Gimenez, M.; Fuego, C.; Caparros-Ruiz, R.; Cano-Garcia, L.; Belmonte, A.; Irigoyen-Oyarzabal, M.; Fernandez-Nebro, A.; [Mena-Vazquez, N.] Univ Malaga, Inst Invest Biomed Malaga IBIMA, UGC Reumatol, Hosp Reg Univ Malaga, Malaga, Spain; [Manrique-Arija, S.] Univ Malaga, Inst Invest Biomed Malaga IBIMA, UGC Reumatol, Hosp Reg Univ Malaga, Malaga, Spain; [Urena-Garnica, I.] Univ Malaga, Inst Invest Biomed Malaga IBIMA, UGC Reumatol, Hosp Reg Univ Malaga, Malaga, Spain; [Ordonez-Canizares, M.] Univ Malaga, Inst Invest Biomed Malaga IBIMA, UGC Reumatol, Hosp Reg Univ Malaga, Malaga, Spain; [Jimenez-Nunez, F.] Univ Malaga, Inst Invest Biomed Malaga IBIMA, UGC Reumatol, Hosp Reg Univ Malaga, Malaga, Spain; [Diaz-Cordoves, G.] Univ Malaga, Inst Invest Biomed Malaga IBIMA, UGC Reumatol, Hosp Reg Univ Malaga, Malaga, Spain; [Rojas-Gimenez, M.] Univ Malaga, Inst Invest Biomed Malaga IBIMA, UGC Reumatol, Hosp Reg Univ Malaga, Malaga, Spain; [Fuego, C.] Univ Malaga, Inst Invest Biomed Malaga IBIMA, UGC Reumatol, Hosp Reg Univ Malaga, Malaga, Spain; [Caparros-Ruiz, R.] Univ Malaga, Inst Invest Biomed Malaga IBIMA, UGC Reumatol, Hosp Reg Univ Malaga, Malaga, Spain; [Cano-Garcia, L.] Univ Malaga, Inst Invest Biomed Malaga IBIMA, UGC Reumatol, Hosp Reg Univ Malaga, Malaga, Spain; [Belmonte, A.] Univ Malaga, Inst Invest Biomed Malaga IBIMA, UGC Reumatol, Hosp Reg Univ Malaga, Malaga, Spain; [Irigoyen-Oyarzabal, M.] Univ Malaga, Inst Invest Biomed Malaga IBIMA, UGC Reumatol, Hosp Reg Univ Malaga, Malaga, Spain; [Romero-Barco, C.] Univ Malaga, Inst Invest Biomed Malaga IBIMA, Hosp Ciln Virgen de la Victoria, UGC Reumatol, Malaga, Spain; [Fernandez-Nebro, A.] Univ Malaga, Inst Invest Biomed Malaga IBIMA, Dept Med & Dermatol, Hosp Reg Univ Malaga,UGC Reumatol, Malaga, SpainItem The Effect of the Inflammatory Bowel Disease Classroom in Nature on the Quality of Life of Patients With Inflammatory Bowel Disease.(2020) Navas-López, Víctor M; Martel, Laura Camacho; Martín-Masot, Rafael; Rubio, María Navalón; Santana, Natalia Ruiz; López, Marta Herrador; Frías Arjona, Almudena; Merino Valero, Víctor M; Ortega Doltz, Verónica; Ramos-Cózar, Sara N; Alcaín Martínez, Guillermo"The IBD Classroom in Nature" is an initiative that combines training and leisure activities in an ideal environment where families and patients can interact with each other. The objective of the present study was to quantify the effect that "The IBD Classroom in Nature" had on the health-related quality-of-life of patients with Inflammatory bowel disease (IBD). We conducted a prospective, analytical study with a pre-post design to demonstrate the impact on health-related quality-of-life (measured with the IMPACT-III questionnaire) of 3 days together in the context of The IBD Classroom in Nature. The study included 13 patients with IBD with a mean age of 12.3 years (interquartile range 11.9-14.5). After "The IBD Classroom in Nature" there was an improvement in the IMPACT-III score with significant improvements in the emotional functioning and body image domains. The present study objectively shows the beneficial effect of group activities focused on the most diverse aspects of their disease.Item CONTRIBUTION OF TRASTUZUMAB TO THE PROGNOSTIC IMPROVEMENT OF HER2-POSITIVE EARLY BREAST CANCER IN SPAIN(Elsevier science inc, 2018-10-01) Ciruelos, E.; Alba, E.; Lopez, R.; Lluch, A.; Martin, M.; Arroyo, I; Navarro, B.; Carcedo, D.; Colomer, R.; Albanell, J.; [Ciruelos, E.] Hosp Univ 12 Octubre, Ctr Oncol Clara Campal, Med Oncol Serv, Madrid, Spain; [Alba, E.] Hosp Univ Reg, Clin Oncol Unit, Malaga, Spain; [Alba, E.] Hosp Univ Virgen de la Victoria, Clin Oncol Unit, Malaga, Spain; [Alba, E.] Inst Invest Bioed Malaga IBIMA, Malaga, Spain; [Lopez, R.] Hosp Clin Univ, Med Oncol Dept, Santiago De Compostela, La Coruna, Spain; [Lopez, R.] Inst Invest Santiago CIBERONC, Santiago De Compostela, La Coruna, Spain; [Lluch, A.] Univ Valencia, Ctr Networked Biomed Canc Res CIBERONC, Hlth Res Inst INCLIVA, Hosp Clin Univ Valencia,Med Oncol Serv, Valencia, Spain; [Martin, M.] Univ Complutense, Med Oncol Serv, Inst Invest Sanitaria Gregorio Maranon, GEICAM,CIBERONC, Madrid, Spain; [Arroyo, I] Roche Farma, Payer Evidence & Hlth Econ Unit, Madrid, Spain; [Navarro, B.] Roche Pharma, Med Dept, Madrid, Spain; [Carcedo, D.] Oblikue Consulting, Barcelona, Spain; [Colomer, R.] Hosp Univ La Princesa, Med Oncol Serv, Madrid, Spain; [Albanell, J.] Hosp Mar, Med Oncol Serv, Barcelona, SpainItem Activity of OSE-2101 in HLA-A2+non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO): Final results of phase III Atalante-1 randomised trial(Elsevier, 2021-09-21) Besse, B.; Garcia Campelo, M. R.; Cobo Dols, M. A.; Quoix, E.; Madroszyk, A.; Felip, E.; Cappuzzo, F.; Denis, F.; Hilgers, W.; Romano, G.; Debieuvre, D.; Baldini, E.; Galetta, D.; Viteri, S.; Phan, M.; Schuette, W.; Zer, A.; Costantini, D.; Dziadziuszko, R.; Giaccone, G.; [Besse, B.] Inst Gustave Roussy, Dept Canc Med, Villejuif, France; [Garcia Campelo, M. R.] Inst Investigac Biomed A Coruna INIBIC, Dept Med Oncol, La Coruna, Spain; [Cobo Dols, M. A.] UGC Oncol Hosp Univ Reg & Virgen Victoria IBIMA, Med Oncol, Malaga, Spain; [Quoix, E.] Hop Univ Strasbourg, Pneumol Dept, Nouvel Hop Civil, Strasbourg, France; [Madroszyk, A.] Inst Paoli Calmettes, Med Oncol, Marseille, France; [Felip, E.] Vall dHebron Univ Hosp, Med Oncol Serv, Thorac Canc Unit, Barcelona, Spain; [Cappuzzo, F.] Ist Nazl Tumori IRCCS Regina Elena, Med Oncol, Rome, Italy; [Denis, F.] Inst Interreg Cancerol Jean Bernard Elsan, Oncol Radiotherapie, Le Mans, France; [Hilgers, W.] Inst Ste Catherine, Med Oncol, Avignon, France; [Romano, G.] Osped Vito Fazzi, Oncol, Lecce, Italy; [Debieuvre, D.] Hop Emile Muller, Serv Pneumol, Mulhouse, France; [Baldini, E.] Osped San Luca, Oncol, Lucca, Italy; [Galetta, D.] Ist Tumori Bari Giovanni Paolo II IRCCS, Med Oncol Dept, Bari, Italy; [Viteri, S.] Hosp Univ Dexeus, Inst Oncol Dr Rosell, Dept Oncol, Barcelona, Spain; [Phan, M.] UOMI Canc Ctr, Clin Mi Tres Torres, Barcelona, Spain; [Schuette, W.] Stephenson Canc Ctr, Oncol, Oklahoma City, OK USA; [Zer, A.] Rabin Med Ctr, Med Oncol, Davidoff Canc Ctr, Beilinson Campus, Petah Tiqwa, Israel; [Costantini, D.] OSE Immunotherapeut, Dev, Paris, France; [Dziadziuszko, R.] Med Univ Gdansk, Oncol & Radiotherapy, Gdansk, Poland; [Giaccone, G.] Weill Cornell Med, Med Oncol, New York, NY USA; OSE ImmunotherapeuticsItem Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB plus ) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C(Elsevier, 2021-09-21) Dziadziuszko, R.; Peters, S.; Gadgeel, S. M.; Mathisen, M. S.; Shagan, S. M.; Felip, E.; Morabito, A.; Cheema, P.; Cobo Dols, M.; Andric, Z.; Barrios, C. H.; Yamaguchi, M.; Dansin, E.; Danchaivijitr, P.; Johnson, M.; Novello, S.; Gandara, D. R.; Schleifman, E.; Wang, J.; Mok, T. S. K.; [Dziadziuszko, R.] Med Univ Gdansk, Oncol & Radiotherapy, Gdansk, Poland; [Peters, S.] Lausanne Univ, Ctr Hosp Univ Vaudois, Oncol, Lausanne, Switzerland; [Gadgeel, S. M.] Henry Ford Hlth Syst, Internal Med, Henry Ford Canc Inst, Detroit, MI USA; [Mathisen, M. S.] Genentech Inc, Prod Dev Oncol, San Francisco, CA USA; [Shagan, S. M.] Genentech Inc, Oncol Biomarker Dev, San Francisco, CA USA; [Schleifman, E.] Genentech Inc, Oncol Biomarker Dev, San Francisco, CA USA; [Felip, E.] Hosp Univ Vall Hebron, Lung Canc Unit, Med Oncol Serv, Barcelona, Spain; [Morabito, A.] IRCCS, Thorac, Ist Nazl Tumori Fdn G Pascale, Naples, Italy; [Cheema, P.] Univ Toronto, William Osler Hlth Syst, Med Oncol, Toronto, ON, Canada; [Cobo Dols, M.] Hosp Univ Reg & Virgen Victoria, Unidad Gest Clin Intercentros Oncol Med, Med Oncol, IBIMA, Malaga, Spain; [Andric, Z.] Univ Hosp Med Ctr Bezanijska Kosa, Med Oncol, Belgrade, Serbia; [Barrios, C. H.] Pontificia Univ Catolica Rio Grande do Sul, Oncol Res Ctr HSL, Internal Med, Porto Alegre, RS, Brazil; [Yamaguchi, M.] Kyushu Canc Ctr, Natl Hosp Org, Dept Thorac Oncol, Otsu, Shiga, Japan; [Dansin, E.] Ctr Oscar Lambret, Med Oncol, Lille, France; [Danchaivijitr, P.] Siriraj Hosp, Dept Med, Fac Med, Bangkok, Thailand; [Johnson, M.] Sarah Cannon Res Inst, Lung, Nashville, TN USA; [Novello, S.] Univ Turin, S Luigi Gonzaga Hosp, Oncol, Orbassano, Italy; [Gandara, D. R.] Univ Calif Davis, Ctr Comprehens Canc, Internal Med & Hematol Oncol, Sacramento, CA USA; [Wang, J.] Genentech Inc, Biostatist, San Francisco, CA USA; [Mok, T. S. K.] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China; F. Hoffmann-La Roche, Ltd.Item Survival of patients with advanced melanoma according to first-line treatment and key prognostic factors: Real-world data from GEM1801 study(Elsevier, 2021-09-21) Marquez-Rodas, I.; Berciano-Guerrero, Miguel-Angel; Munoz Couselo, E.; Manzano, J. L.; Crespo Herrero, G.; Soria, A.; Cerezuela, P.; Puertolas Hernandez, T.; Berrocal, A.; Majem Tarruella, M.; Bellido Hernandez, L.; Espinosa, E.; Garcia Castano, A.; Medina Martinez, J.; Fernandez Morales, L. A.; Aguado de la Rosa, C.; Gutierrez Sanz, L.; Lopez Castro, R.; Ayala de Miguel, P.; Martin Algarra, S.; [Marquez-Rodas, I.] Hosp Gen Univ Gregorio Maranon, Med Oncol, Madrid, Spain; [Berciano Guerrero, M. A.] HURyVV Hosp Univ Reg & Virgen Victoria Malaga, IBIMA Inst Invest Biomed Malaga, Unidad Intercentros Oncol, Oncol Dept, Malaga, Spain; [Munoz Couselo, E.] Vall dHebron Inst Oncol, Med Oncol, Barcelona, Spain; [Manzano, J. L.] H Germans Trias & Pujol, Med Oncol, ICO Badalona, Barcelona, Spain; [Crespo Herrero, G.] Hosp Univ Burgos, Med Oncol, Burgos, Spain; [Soria, A.] Hosp Univ Ramon y Cajal, Med Oncol, Madrid, Spain; [Cerezuela, P.] Hosp Virgen Arrixaca, Med Oncol, Murcia, Spain; [Puertolas Hernandez, T.] Hosp Miguel Servet, Med Oncol Dept, Zaragoza, Spain; [Berrocal, A.] Hosp Gen Univ Valencia, Med Oncol, Valencia, Spain; [Majem Tarruella, M.] Hosp Santa Creu & Sant Pau, Med Oncol, Barcelona, Spain; [Bellido Hernandez, L.] Complejo Asistencial Univ Salamanca, Med Oncol, Salamanca, Spain; [Espinosa, E.] Hosp Univ La Paz, Med Oncol, Madrid, Spain; [Garcia Castano, A.] Hosp Univ Marques Valdecilla, Med Oncol, Santander, Spain; [Medina Martinez, J.] Hosp Virgen Salud, Med Oncol, Toledo, Spain; [Fernandez Morales, L. A.] Parc Tauli Univ Hosp, Med Oncol, Sabadell, Spain; [Aguado de la Rosa, C.] Hosp Clin San Carlos, Med Oncol, Madrid, Spain; [Gutierrez Sanz, L.] Hosp Univ Puerta Hierro, Med Oncol, Madrid, Spain; [Lopez Castro, R.] Hosp Clin Univ Valladolid, Med Oncol, Valladolid, Spain; [Ayala de Miguel, P.] Univ Hosp San Pedro Alcantara, Med Oncol, Caceres, Spain; [Martin Algarra, S.] Clin Univ Navarra, Oncol Dept, Pamplona, Spain; Novartis; Pierre Fabre; Roche; Incyte; BMS; MSD